Latest Headlines

  1. Orasis Pharmaceuticals Announces Australia Submission Of A New Drug Application For Beska For The Treatment Of Presbyopia 7/15/2026

    Orasis Pharmaceuticals and Aspen Australia announced that Aspen has submitted a New Drug Application in Australia to the Therapeutic Goods Administration (TGA) for the review and approval of BESKA (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults (known as QLOSI in the US market).

  2. Anova And Nouveau Biosciences Announce Partnership To Deliver Clinical Trials Of Kromastat For The Treatment Of Relapsed Or Refractory Cutaneous And Peripheral T-Cell Lymphoma 7/15/2026

    Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, today announced its partnership with Nouveau Biosciences, Inc. to conduct cancer focused clinical trials for their lead asset Kromastat. Nouveau Biosciences is a biotechnology company pioneering novel targeted nanomedicines to improve cancer therapy.

  3. CellCarta Launches Digital Pathology And AI Consortium To Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development 7/15/2026

    CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced the launch of its Global Digital Pathology and AI Consortium, a curated ecosystem of leading digital pathology, artificial intelligence and precision diagnostics innovators designed to help biopharma sponsors accelerate biomarker discovery, patient stratification, clinical trial execution and companion diagnostic strategy across oncology, autoimmune, Alzheimer's disease and other indications as needed.

  4. Kelun-Biotech And Harbour BioMed Announce NMPA Approval Of IND Application For SKB575/HBM7575 For The Treatment Of Asthma 7/15/2026

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for SKB575/HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of asthma.

  5. Insilico Medicine And Bora Pharmaceuticals Announce Strategic Alliance For AI-Driven Drug Discovery And Development 7/14/2026

    Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing.

  6. Lynk Pharmaceuticals Announces Completion Of Patient Enrollment In Phase III Clinical Trial Of Zemprocitinib For Ankylosing Spondylitis 7/14/2026

    Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the Phase III clinical trial evaluating its core product zemprocitinib capsules for the treatment of active ankylosing spondylitis (AS).

  7. Atrium Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ATR 1072 For Treatment Of PRKAG2 Syndrome 7/14/2026

    Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome.

  8. HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102, A Novel Oral NLRP3 Inhibitor For Cardiovascular Risk Reduction 7/14/2026

    Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, on dosing the first participant in QUELL-CV, a Phase 2 proof-of-concept clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor.

  9. Atea Pharmaceuticals Initiates First-In-Human Phase 1 Clinical Trial Of AT-587 For The Treatment Of Hepatitis E Virus 7/14/2026

    Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection.

  10. Apnimed Announces FDA Acceptance Of New Drug Application For AD109, An Investigational Oral Pill To Treat Adults With Obstructive Sleep Apnea (OSA) 7/14/2026

    Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for review the New Drug Application ("NDA") filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea ("OSA").